This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Potassium sodium hydrogen citrate is a urine alkalinizing agent indicated in the treatment and prevention of uric acid, oxalate, phosphate, and cystine stones.
- Generic Name
- Potassium sodium hydrogen citrate
- DrugBank Accession Number
- DB16585
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Potassium sodium hydrogen citrate (DB16585)
- Weight
- Average: 582.477
Monoisotopic: 581.878047 - Chemical Formula
- C12H12K3Na3O15
- Synonyms
- Hexapotassium hexasodium pentacitrate hydrate
- Hexapotassium hexasodium pentacitrate hydrate complex
- Potassium sodium hydrogen citrate
- Sodium potassium hydrogen citrate
- Uralyt-U
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Calcium oxalate urolithiasis •••••••••••• •••••••• ••• •••••••• Treatment of Uric acid stones •••••••••••• •••••••• ••• •••••••• Adjunct therapy in treatment of Cystine renal calculi •••••••••••• •••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X6T6YN87SU
- CAS number
- 55049-48-4
- InChI Key
- IYKMDRMCUIFHRA-UHFFFAOYSA-H
- InChI
- InChI=1S/2C6H8O7.3K.3Na.H2O/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;;1H2/q;;6*+1;/p-6
- IUPAC Name
- tripotassium trisodium bis(2-hydroxypropane-1,2,3-tricarboxylate) hydrate
- SMILES
- [Na+].[Na+].[Na+].[K+].[K+].[K+].[H]O[H].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
References
- General References
- BASG: Uralyt U (Potassium Sodium Hydrogen Citrate) Oral Granules for Solution [Link]
- External Links
- ChemSpider
- 149844
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Kidney Stones 1 1, 2 Unknown Status Treatment Kidney Stones 1 Not Available Recruiting Not Available Uric Acid Stones 1 Not Available Unknown Status Treatment Hyperuricemia / Uric Acid Stones 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule, for solution Oral Granule, for solution Oral 2.4 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1.3 Chemaxon pKa (Strongest Acidic) 3.05 Chemaxon pKa (Strongest Basic) -4.2 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 140.62 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 68.14 m3·mol-1 Chemaxon Polarizability 14.23 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at February 10, 2021 21:11 / Updated at May 05, 2021 20:33